Research programme: chimeric antigen receptor T-cell therapeutics - Celyad

Drug Profile

Research programme: chimeric antigen receptor T-cell therapeutics - Celyad

Alternative Names: CAR NKp/B7H6; CAR-NKp30/B7H6; CAR-T B7H6; CAR-T NKG2Dß; CAR-T NKp30; CYAD-03; CYAD-04; CYAD-05; NKR-3 Allogeneic; NKR-3 Autologous; TCR-deficient NKR T-cell therapy - Celyad

Latest Information Update: 01 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dartmouth College
  • Developer Celyad
  • Class CAR-T cell therapies
  • Mechanism of Action B7 antigen modulators; Immunostimulants; Natural cytotoxicity triggering receptor 3 modulators; Natural killer cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 May 2017 Celyad has patent protection for allogeneic TCR-deficient CAR T-cells in USA
  • 02 May 2017 Novartis in-licenses intellectual property rights related to allogeneic CAR-T cells from Celyad
  • 02 Mar 2016 Celyad has patent protection for allogeneic TCR-deficient CAR T-cells in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top